Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

ABSTRACT The innate lymphoid cell (ILC) family includes natural killer (NK) cells, recognised for over 50 years, as well as several more recently identified populations. Over the past 15 years, ILCs have emerged as key orchestrators of tissue homeostasis and inflammation. To build upon the early promise of cancer immunotherapies, it is essential to better understand the pathways regulating the composition of, and immunosuppressive mechanisms that dominate many solid cancers and effectively curtail or block T cell responses. Given their residence within most tissues, how these cellular sentinels influence tumour development and progression remains an active area of both discovery and more translationally focused research. By defining precisely how different immunosuppressive pathways form, rationalised immunotherapy combinations can be devised to specifically target these. Current evidence indicates that for each ILC subset, both pro‐ and anti‐tumourigenic roles are possible, likely reflecting local cues within different tissues and contexts. Here, we seek to concisely review some of the prevailing data describing ILC contributions to tumour immunity and highlight some of the challenges that still exist in fully dissecting these mechanisms.

More information Original publication

DOI

10.1002/eji.70041

Type

Journal article

Publisher

Wiley

Publication Date

2025-09-01T00:00:00+00:00

Volume

55